About Us
Medical Affairs 360 is a boutique medical advisory firm that provides specialized support to pharmaceutical and biotechnology companies. We deliver expert Medical Affairs, Clinical Development, and Drug Safety services to our partner organizations. Our consultants and advisors bring over 25 years of experience supporting successful, market-leading pharmaceutical and biotechnology products.
Leadership Team
KENNETH TONG
PRESIDENT AND FOUNDER
Kenneth Tong is President and Founder of Medical Affairs 360 LLC, a medical advisory and consulting firm to biopharmaceutical companies. Dr. Tong has over 30 years of experience in major biotechnology and Fortune 100 pharmaceutical companies. Dr. Tong has extensive experience in medical affairs planning and strategy, medical department creation and operations, and product launch and commercialization. Dr. Tong played a key role in product lifecycle planning from clinical development to product launch for commercially successful products including: BIAXIN®(clarithromycin), LOTRONEX® (alosetron), BOTOX® (botulinum toxin A), Zegerid® (omeprazole/sodium bicarbonate), RITUXAN® (rituximab), IMBRUVICA® (ibrutinib), and VITRAKVI® (larotrectinib). His therapeutic experience includes the areas of neurology, gastroenterology, and oncology.
Dr. Tong began his scientific career at Merck & Co. Inc., and held management positions at Abbott Laboratories Inc. More recently, Dr. Tong was head of Drug Safety and Pharmacovigilance at Loxo Oncology (Acquired by Eli Lilly and Company), Sr Director of Medical Affairs and Drug Safety at Santarus Inc. (acquired by Salix Pharmaceuticals), and Director, Global Medical Affairs at Allergan Inc (Acquired by AbbVie Inc.).
Dr. Tong obtained his Doctor of Pharmacy degree from The University of California, San Francisco (UCSF) and Biology at The University of California, Irvine (UCI).
DANA LEE
CLINICAL DEVELOPMENT OFFICER
Dana Lee is the Clinical Development Officer at Medical Affairs 360 LLC. Dr. Lee has over 30 years of global experience in oncology, rare diseases, endocrinology, and neurology specializing in clinical science and translational drug development across biologics, bi-specifics/ADCs, peptides, and small molecule programs. Dr. Lee played a key role in successful INDs and NDA submissions leading to product approvals for IMBRUVICA® (ibrutinib) in chronic lymphocytic leukemia, BYETTA® (exenatide), BOTOX®(botulinum toxin A) for hyperhidrosis, and RITUXAN® (rituximab) for Non-Hodgkin’s Lymphoma.
Dr. Lee began her medical research career at Cedars-Sinai Medical Center and held management positions at IDEC Pharmaceuticals (acquired by Biogen Inc.), Amylin Pharmaceuticals (acquired by Bristol-Myers Squibb), Allergan (acquired by AbbVie Inc.), and Pharmacyclics Inc (acquired by AbbVie Inc.). Dr. Lee is currently on the Board of Directors at The Preuss School, University of California, San Diego (UCSD).
Dr. Lee obtained her Doctor of Pharmacy degree from The University of California, San Francisco (UCSF).
Philip K. Yeung
DIRECTOR, CLINICAL EVIDENCE & ANALYTICS
Philip Yeung is a Clinical Evidence & Analytics Strategist with over two decades of experience transforming complex health data into strategic evidence that informs clinical practice, regulatory strategy, and market access. He specializes in evidence generation, advanced biostatistics, and strategic publication planning for the pharmaceutical, biotechnology, and medical device industries, partnering with clients to align scientific rigor with business objectives.
Dr. Yeung has led the full evidence lifecycle—from study design and advanced analytics to publication and commercialization—across oncology, gastroenterology, infectious disease, diabetes, respiratory medicine, and rare diseases such as hereditary angioedema, neurotrophic keratitis, and eosinophilic esophagitis. His work spans real-world evidence (RWE), health economics and outcomes research (HEOR), and AI-driven medical imaging, with various publications and presentations at renowned journals and medical societies.
Previously, Dr. Yeung held management roles at Santarus Inc. and include roles at Pharmacia Corporation (Acquired by Pfizer Inc.) and at Watson Pharmaceuticals (now Teva Pharmaceuticals) along with ongoing academic collaborations, including research affiliate positions at the University of California, San Diego’s (UCSD) Blood and Bone Marrow Transplant Department and AI-focused oncology projects with the University of Kansas Medical Center’s Reliable Intelligence and Medical Innovation (RIMI) Lab.
Dr. Yeung holds a Doctor of Pharmacy degree from the University of Illinois at Chicago, a Master of Science in Clinical Research (Biostatistics) from the University of California, San Diego (UCSD), a Master of Science in Applied Pharmacoeconomics from the University of Florida, and an MBA from Lake Forest Graduate School of Management.
ALEX LEE
DIRECTOR OF INFORMATION TECHNOLOGY
Alex Lee is Director of Information Technology at Medical Affairs 360 LLC. Alex has over two decades of expertise designing, building, and supporting IT infrastructure for small to mid-sized businesses and specialized medical-affairs environments. He is skilled in network architecture, email and cloud systems, database administration, and cybersecurity. He has extensive background implementing and managing Oracle Argus and SafetyEasy safety databases, including validation, reporting, and data migration. Alex is adept in project management for call-center systems, IT SOP development, and full-spectrum hardware, server, and network support.
Alex was on the informational technology advisory board at Stanbridge College. Alex obtained his Bachelor of Science in chemistry from The University of California, Berkeley.